SUD919CL2Y en es it fr

SUD919CL2Y Brand names, SUD919CL2Y Analogs

SUD919CL2Y Brand Names Mixture

  • No information avaliable

SUD919CL2Y Chemical_Formula


SUD919CL2Y RX_link

SUD919CL2Y fda sheet

SUD919CL2Y msds (material safety sheet)

SUD919CL2Y Synthesis Reference

No information avaliable

SUD919CL2Y Molecular Weight

211.324 g/mol

SUD919CL2Y Melting Point

No information avaliable

SUD919CL2Y H2O Solubility

No information avaliable

SUD919CL2Y State



No information avaliable

SUD919CL2Y Dosage Forms


SUD919CL2Y Indication

For the treatment of signs and symptoms of idiopathic Parkinson's disease

SUD919CL2Y Pharmacology

Pramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that Pramipexole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum.

SUD919CL2Y Absorption

No information avaliable

SUD919CL2Y side effects and Toxicity

No information avaliable

SUD919CL2Y Patient Information

Patients should be instructed to take MIRAPEX only as prescribed.

Patients should be informed that hallucinations can occur and that the elderly are at a higher risk than younger patients with Parkinson 's disease.

Patients may develop postural (orthostatic) hypotension, with or without symptoms such as dizziness, nausea, fainting or blackouts, and sometimes, sweating. Hypotension may occur more frequently during initial therapy. Accordingly, patients should be cautioned against rising rapidly after sitting or lying down, especially if they have been doing so for prolonged periods and especially at the initiation of treatment with MIRAPEX.

Patients should be advised that MIRAPEX may cause somnolence and that they should neither drive a car nor operate other complex machinery until they have gained sufficient experience on MIRAPEX to gauge whether or not it affects their mental and/or motor performance adversely. Because of the possible additive sedative effects, caution should also be used when patients are taking other CNS depressants in combination with MIRAPEX.

Because the teratogenic, potential of pramipexole has not been completely established in laboratory animals, and because experience in humans is limited, patients should be advised to notify their physicians if they become pregnant or intend to become pregnant during therapy.

Because of the possibility that pramipexole may be excreted in breast milk, patients should be advised to notify their physicians if they intend to breast-feed or are breast-feeding an infant.

If patients develop nausea, they should be advised that taking MIRAPEX with food may reduce the occurrence of nausea.

SUD919CL2Y Organisms Affected

Humans and other mammals